CN1845731A - 用于血糖控制的联合治疗 - Google Patents

用于血糖控制的联合治疗 Download PDF

Info

Publication number
CN1845731A
CN1845731A CNA2004800251945A CN200480025194A CN1845731A CN 1845731 A CN1845731 A CN 1845731A CN A2004800251945 A CNA2004800251945 A CN A2004800251945A CN 200480025194 A CN200480025194 A CN 200480025194A CN 1845731 A CN1845731 A CN 1845731A
Authority
CN
China
Prior art keywords
diabetes
glutaminyl
pharmaceutically acceptable
insulin
thiazolidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800251945A
Other languages
English (en)
Chinese (zh)
Inventor
汉斯-乌尔里希·德穆特
康拉德·格隆德
马蒂亚斯·霍夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of CN1845731A publication Critical patent/CN1845731A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CNA2004800251945A 2003-09-02 2004-09-02 用于血糖控制的联合治疗 Pending CN1845731A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
US60/499,535 2003-09-02

Publications (1)

Publication Number Publication Date
CN1845731A true CN1845731A (zh) 2006-10-11

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800251945A Pending CN1845731A (zh) 2003-09-02 2004-09-02 用于血糖控制的联合治疗

Country Status (14)

Country Link
US (1) US20060287251A1 (https=)
EP (1) EP1663200A2 (https=)
JP (1) JP2007504213A (https=)
KR (1) KR20060119927A (https=)
CN (1) CN1845731A (https=)
AU (1) AU2004267955A1 (https=)
BR (1) BRPI0413204A (https=)
CA (1) CA2536432A1 (https=)
EA (1) EA200600356A1 (https=)
IL (1) IL173844A0 (https=)
MX (1) MXPA06002127A (https=)
NO (1) NO20061085L (https=)
WO (1) WO2005020983A2 (https=)
ZA (1) ZA200601770B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101588843A (zh) * 2006-11-29 2009-11-25 医药研究委员会 检测
CN107693783A (zh) * 2011-10-28 2018-02-16 赛诺菲-安万特德国有限公司 2型糖尿病的治疗方案

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP2552952A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
JP2005527504A (ja) * 2002-02-28 2005-09-15 プロシディオン・リミテッド グルタミニルを基礎するｄｐｉｖ阻害剤
WO2004031374A2 (en) * 2002-09-18 2004-04-15 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101588843A (zh) * 2006-11-29 2009-11-25 医药研究委员会 检测
CN107693783A (zh) * 2011-10-28 2018-02-16 赛诺菲-安万特德国有限公司 2型糖尿病的治疗方案

Also Published As

Publication number Publication date
MXPA06002127A (es) 2006-05-31
EA200600356A1 (ru) 2006-08-25
EP1663200A2 (en) 2006-06-07
NO20061085L (no) 2006-05-31
CA2536432A1 (en) 2005-03-10
US20060287251A1 (en) 2006-12-21
JP2007504213A (ja) 2007-03-01
WO2005020983A3 (en) 2005-07-28
KR20060119927A (ko) 2006-11-24
IL173844A0 (en) 2006-07-05
ZA200601770B (en) 2007-07-25
WO2005020983A2 (en) 2005-03-10
AU2004267955A1 (en) 2005-03-10
BRPI0413204A (pt) 2006-10-03

Similar Documents

Publication Publication Date Title
CN1290848C (zh) 作为治疗或预防糖尿病的二肽基肽酶抑制剂的β－氨基四氢咪唑并(1,2－A)吡嗪和四氢三唑并(4,3－A)吡嗪
Thornberry et al. Discovery of JANUVIA™(Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes.
CN1089584C (zh) 动脉硬化和黄瘤的治疗
CN1098838C (zh) 被取代的N－(吲哚－2－羰基)－β－丙氨酰胺与作为抗糖尿病药的衍生物
CN1178912C (zh) 旋转异构酶活性的小分子抑制剂
CN1622941A (zh) 基于谷氨酰胺酰基的dpiv抑制剂
CN1164573C (zh) 新的α-氨基酸化合物、其制备方法和包含它们的药物组合物
CN1230162C (zh) 改进释放胰岛素致敏剂和另一抗糖尿病药的药用组合物
CN1720042A (zh) DPP－IV抑制剂与PPAR－α化合物的组合
CN101035522A (zh) Dpp－ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
CN1374082A (zh) 糖原磺酸化酶抑制剂的用途
CN1655786A (zh) Dpp iv抑制剂和心血管化合物的组合
CN1083715C (zh) 胰岛素敏化物治疗肾病的应用
CN1582149A (zh) 新的二肽基肽酶iv抑制剂和它们用于降低血压水平的用途
CN1918131A (zh) 新的谷氨酰胺酰基环化酶抑制剂
CN1708486A (zh) 二苯基乙烯化合物的新型杂环类似物
CN1660060A (zh) (－)(3－三卤代甲基苯氧基)(4－卤代苯基)乙酸衍生物在治疗高尿酸血症中的应用
CN1901938A (zh) Dpp－iv抑制剂与抗肥胖药或食欲调节药的组合
CN1642904A (zh) 那格列奈的盐
CN1839131A (zh) 吡咯烷甲腈类化合物及其作为dpp－iv抑制剂的应用
CN1845731A (zh) 用于血糖控制的联合治疗
CN1728992A (zh) 具有降低血清葡萄糖和降低血清脂质活性的α－苯硫基羧酸和α－苯氧基羧酸的用途
CN1208066C (zh) 应用环醚制备影响葡萄糖耐量的药物
CN1257893C (zh) 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂
EP2351567B1 (en) Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication